Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760410 | 0.79 | MAPT (0.47) | MAPTALDH1A1TDP1POLBPKM | |
| SCHEMBL2457768 | 0.78 | NOS1 (0.50) | NOS1NOS2MAPTALDH1A1TDP1 | |
| SCHEMBL6966179 | 0.76 | MAPT (0.41) | NOS1NOS2MAPTALDH1A1TDP1 | |
| SCHEMBL18463627 | 0.73 | ALDH1A1 (0.52) | MAPTALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL1558637 | 0.73 | ALDH1A1 (0.36) | NOS1NOS2MAPTALDH1A1TDP1 | |
| SCHEMBL1559362 | 0.72 | L3MBTL1 (0.40) | MAPTALDH1A1TDP1POLBTSHR | |
| SCHEMBL26695904 | 0.72 | MAPT (0.35) | NOS1NOS2MAPTALDH1A1TDP1 | |
| SCHEMBL20555646 | 0.72 | HTT (0.38) | MAPTALDH1A1TDP1POLBHSD17B10 | |
| SCHEMBL22785871 | 0.72 | MAPT (0.35) | NOS1NOS2MAPTALDH1A1TDP1 | |
| SCHEMBL2182301 | 0.72 | CYP3A4 (0.36) | MAPTALDH1A1TDP1POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111235597-B | Synthesis method of nitroazole energetic compound | 南京理工大学 | 2020-10-30 | — | — | CN | disclosed |
| CN-111235597-A | Synthesis method of nitroazole energetic compound | 南京理工大学 | 2020-06-05 | — | — | CN | disclosed |
| EP-2508182-B1 | Hydralazine for use in the treatment of age-related macular degeneration | TEXAS A & M UNIV SYS (US) | 2016-07-06 | — | — | EP | disclosed |
| EP-2508183-B1 | Interleukin-1 blocker for use in the treatment of age-related macular degeneration | TEXAS A & M UNIV SYS (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130059841-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-03-07 | — | — | US | disclosed |
| US-8318741-B2 | Therapeutic compositions and methods | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2508182-A1 | Hydralazine for use in the treatment of age-related macular degeneration | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2508183-A1 | Interleukin-1 blocker for use in the treatment of age-related macular degeneration | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20120196868-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120115959-A1 | Therapeutic Compositions And Methods | THE TEXAS A&M UNIVERSITY SYSTEM | 2012-05-10 | — | — | US | disclosed |
| US-20120071485-A1 | Therapeutic Compositions And Methods | THE TEXAS A&M UNIVERSITY SYSTEM | 2012-03-22 | — | — | US | disclosed |
| US-8088773-B2 | Therapeutic compositions and methods | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-01-03 | — | — | US | disclosed |
| US-5885935-A | Sulfonamide herbicides | AGREVO UK LIMITED (GB) | 1999-03-23 | — | — | US | disclosed |
| EP-0625970-B1 | SULFONAMIDE HERBICIDES | AGREVO UK LTD (GB) | 1997-09-17 | — | — | EP | disclosed |
| US-5559081-A | Sulfonamide herbicides | AGREVO UK LIMITED (GB) | 1996-09-24 | — | — | US | disclosed |
| EP-0625970-A1 | SULFONAMIDE HERBICIDES. | AGREVO UK LTD (GB) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993009099-A2 | SULFONAMIDE HERBICIDES | AGREVO UK LIMITED (GB) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115959-A1 | Therapeutic Compositions And Methods | PDE6C, PDE6H, PDE6D | NOS1 805/4885NOS2 492/4885MAPT 1670/4885 |
| US-20120071485-A1 | Therapeutic Compositions And Methods | PDE6H, PDE6C, PDE6D | NOS1 2130/4885NOS2 1328/4885MAPT 1187/4885 |
| US-20120196868-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PDE6H, PDE6C, PDE6D | NOS1 2130/4885NOS2 1328/4885MAPT 1187/4885 |
| US-20130059841-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PDE6H, PDE6C, PDE6D | NOS1 2130/4885NOS2 1328/4885MAPT 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.